Dietary oligosaccharides have enjoyed a longstanding tradition in promoting health, especially within Asian cultures where they have been utilized for generations. However, it was only in 1995 that researchers Glenn Gibson and Marcel Roberfroid truly broadened and formalized the prebiotic concept. They described it as nondigestible food ingredients that positively influence the host by selectively promoting the growth and or activity of one or a limited number of bacterial species that are already present in the colon, thereby working to enhance the overall health of the host.
At that time, the criteria for identifying a substance as a prebiotic were significantly limited by the available microbiological techniques and methodologies. For a compound to qualify, it needed to fulfill several key requirements, which included the following:
As a result of these constraints, early scientific investigations predominantly centered on fructooligosaccharides, commonly abbreviated as FOS. These particular molecules earned their status as prebiotics through robust evidence showing their unique capacity to encourage the proliferation of bifidobacteria, a bacterial genus widely acknowledged for its advantageous properties, much like lactobacilli, particularly when tested in human fecal culture models.
In the three decades that have followed the initial proposal, the prebiotic definition has seen several essential refinements. These changes have been driven by groundbreaking advancements in genomics and an ever-expanding knowledge base regarding the intricacies of the microbiome ecosystem. A landmark moment came with the 2017 consensus statement from the International Scientific Association for Probiotics and Prebiotics, or ISAPP, which refined the definition to encompass a substrate that is selectively utilized by microorganisms residing in the host, ultimately delivering a health benefit. This updated perspective was further solidified and endorsed in the 2025 expert recommendations, ensuring its continued relevance.
The task facing the expert panel was to craft a definition expansive enough to incorporate emerging discoveries yet precise enough to foster agreement among scientists, industry professionals, and regulatory bodies. The revisions in 2017 and 2025 brought about substantial broadenings in several critical areas related to prebiotic applications:
The understanding of prebiotics has progressed far beyond a singular emphasis on bifidobacteria and lactobacilli. It now embraces a more comprehensive ecological viewpoint. A prebiotic effect is deemed selective when changes in the microbiome-be they in composition, functionality, or overall ecology-can be robustly associated with tangible health improvements through scientific validation. Moreover, the framework now explicitly includes bacterial cross-feeding mechanisms, where alterations in microbial communities extend beyond the initial substrate utilizers and are still regarded as valid selective modulations.
No longer confined solely to the intestinal environment, prebiotics are now applicable to various other anatomical locations. These include the skin, the oral cavity, and the urogenital tract, all of which have been identified as viable sites for targeted prebiotic strategies to support microbial balance and health.
By framing prebiotics as substrates in general, the definition has welcomingly extended to non-carbohydrate compounds. Examples encompass polyphenols and polyunsaturated fatty acids, known as PUFAs, as long as they satisfy the rigorous standards of selective microbial utilization coupled with demonstrable health advantages.
Marking the 30th anniversary, a key editorial publication underscores the alignment of prebiotics within the One Health initiative. This holistic approach interconnects the health of humans, animals, and entire ecosystems. Given that the majority of prebiotics originate from plants or fungi, they serve as a vital bridge between plant-based physiological processes, such as resistance to environmental stresses, and the pursuit of sustainable nutrition on a global scale.
A recurring challenge highlighted in the 2025 publications revolves around demonstrating causal relationships in human intervention studies. Specifically, it concerns confirming that microbiome alterations directly mediate the health outcomes observed. Although the definition presupposes such causality, achieving definitive proof within the intricate dynamics of a microbial ecosystem remains exceptionally challenging. Therefore, while pursuing causality through advanced molecular techniques and statistical analyses is highly encouraged, it is not presently an unbreakable prerequisite for prebiotic classification, as long as a compelling, scientifically grounded hypothesis is presented.
In an effort to promote transparency and curb the inappropriate use of the prebiotic label in academic research as well as commercial products, experts led by Hutkins and colleagues have delineated precise minimum standards for prebiotic categorization. These standards are designed to uphold scientific integrity and consumer trust, and they include:
Even with these comprehensive guidelines in place, several persistent hurdles continue to complicate prebiotic research and development. Among them are the intricacies of proving causality amid the fiercely competitive niches within the gut environment, adapting to diverse international regulatory landscapes, and addressing technical constraints like challenges in sampling various segments of the gastrointestinal tract along with significant inter-individual variations in microbial responses.
